Related resources
Full-text held externally
- PMID: 16225593
- UKPMCID: 16225593
- DOI: 10.1111/j.1365-2133.2005.06880.x
Search for item elsewhere
University researcher(s)
Academic department(s)
The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
The British journal of dermatology. 2005;153(5):869-73.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 16225593
- UKPMCID: 16225593
- DOI: 10.1111/j.1365-2133.2005.06880.x
Abstract
The study of pharmacogenetics will optimize the use of systemic therapies in dermatology. Directed prescription of azathioprine dependent on phenotypic expression of the thiopurine methyltransferase gene is now accepted practice. To some extent other, older drugs have been neglected. We look at the role that pharmacogenetics could play in the use of methotrexate for psoriasis, focusing on known polymorphisms in the folate metabolic pathway.